PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy

Autor: Malcolm A.S. Moore, Pawel Zalewski, Pablo Cano, Annie Beaudoin, Scot Dowden, Yoo-Joung Ko, Sukhbinder Dhesy-Thind, John Stewart, Christine Cripps, Thuan Do, Muhammad Zulfiqar, Helene Grassin, Sharlene Gill, Wendy Yin Han Lam

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(32)

Purpose The standard of care for second-line therapy in patients with advanced pancreatic cancer after gemcitabine-based therapy is not clearly defined. The CONKO-003 phase III study reported a survival benefit with second-line fluorouracil (FU) and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebb442008464a56c9ad59733f22b5bbd
https://pubmed.ncbi.nlm.nih.gov/28113022

PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.

Autor: Gill S; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Ko YJ; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Cripps C; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Beaudoin A; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Dhesy-Thind S; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Zulfiqar M; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Zalewski P; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Do T; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Cano P; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Lam WYH; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Dowden S; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Grassin H; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Stewart J; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada., Moore M; Sharlene Gill and Malcolm Moore, BC Cancer Agency, Vancouver; Muhammad Zulfiqar, BC Cancer Agency, Abbotsford; Thuan Do, BC Cancer Agency, Surrey; Wendy Yin Han Lam, Burnaby Hospital Cancer Centre, Burnaby, British Columbia; Yoo-Joung Ko, Sunnybrook Health Sciences Centre; Malcolm Moore, Princess Margaret Hospital, Toronto; Christine Cripps, Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder Dhesy-Thind, Juravinski Cancer Centre, Hamilton; Pawel Zalewski, RSM Durham Regional Cancer Centre, Oshawa; Pablo Cano, Sudbury Regional Hospital, Sudbury, Ontario; Annie Beaudoin, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Helene Grassin and John Stewart, Sanofi Canada, Laval, Quebec; and Scot Dowden, Alberta Health Service, Calgary, Alberta, Canada.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 Nov 10; Vol. 34 (32), pp. 3914-3920. Date of Electronic Publication: 2016 Sep 30.